2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14A.13 Discovery and Clinical Application of Potential Prognostic Genes for Clinical Outcome in Malignant Pleural Mesothelioma

P2.14A.13 Discovery and Clinical Application of Potential Prognostic Genes for Clinical Outcome in Malignant Pleural Mesothelioma

Back to course

Pdf Summary

The study, conducted by the Department of Thoracic Surgery at Nagoya University Graduate School of Medicine, focuses on identifying potential prognostic genes to predict clinical outcomes in malignant pleural mesothelioma (MPM), a disease with a poor prognosis. The research employed a comprehensive genetic analysis using the TCGA MPM dataset, which included gene expression and survival data for 85 patients. <br /><br />A Cox proportional hazards model was used on 20,532 genes to identify those related to prognosis, followed by clustering and Kaplan-Meier analyses to assess their clinicopathological significance. In particular, the study highlighted the CHST4 gene as a promising biomarker for predicting postoperative outcomes in MPM. Validation involved immunohistochemical (IHC) analysis on tissue samples from MPM patients who achieved macroscopic complete resection.<br /><br />The findings were validated with Kaplan-Meier survival curves, demonstrating a significant distinction in survival and recurrence based on CHST4 expression. The study emphasizes the potential of these genomic insights to guide surgical decisions and develop a new classification system for MPM, thereby improving patient management.<br /><br />Despite recent results from the MARS 2 trial, which showed no significant survival benefit between surgical and non-surgical treatment for MPM, this research suggests the need for reliable prognostic biomarkers to identify patients who might benefit from surgery. The identification of CHST4 as a biomarker could inform future treatments and strategies, though further studies involving a larger cohort are recommended for validation.<br /><br />Overall, the study provides a foundation for the development of improved prognostic tools, which could significantly influence the management and therapeutic approaches for patients with MPM.

Asset Subtitle

Taketo Kato

Meta Tag

Speaker Taketo Kato

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

malignant pleural mesothelioma

prognostic genes

CHST4 biomarker

TCGA MPM dataset

Cox proportional hazards model

Kaplan-Meier analysis

immunohistochemical analysis

surgical decisions

MARS 2 trial

genomic insights